before a Supreme Court decision seems doubtful. Additionally, Teva reported a 19% decline in Copaxone sales this quarter, which ..... competitive landscape of the multiple sclerosis market. Additionally, Teva has now shifted nearly 50% of its patient base to the new three
Teva Pharmaceutical Industries Limited (NYSE: TEVA ) Q2 2014 Earnings Conference Call July 31, 2014 8:00 am ET Executives Kevin C. Mannix - VP, Head of Investor Relations Erez Vigodman - President and CEO Eyal Desheh - Group EVP and CFO Richard
* Now sees 2014 EPS $4.50-$4.80 with Copaxone competition
JERUSALEM, July 31 (Reuters) - Israeli industrialist Benny Landa said his campaign to improve corporate governance at Teva Pharmaceutical Industries was delivering results, despite losing a shareholder vote at the world's largest generic drugmaker.
July 31 (Reuters) - Teva Pharmaceutical Industries Ltd said:
Teva Pharmaceutical Industries (NYSE: TEVA ) Q2 results : Total Revenues: $5,045M (+2.5%), Generic Medicine: $2,515M (+4.3%), Specialty Medicine: $2,027M (-1.2%); Operating Income: $1,094M (+14.8
TEL AVIV, July 31 (Reuters) - Teva Pharmaceutical Industries reported on Thursday higher quarterly earnings that beat analysts' estimates by one cent due in part to the launch of several generic products in the United States.
Teva Pharmaceutical (NYSE: TEVA ): Q2 EPS of $1.23 beats by $0.02 . Revenue of $5.04B (+2.4% Y/Y) misses by $40M . Press Release Post your comment!
July 30 (Reuters) - Israeli drugmaker Teva Pharmaceuticals Industries said on Wednesday it turned back efforts by Israeli industrialist Benny Landa to shake up the company's board of directors, with shareholders approving all of the company's proposals and board nominations.
PNW , PPL , PRFT , PWR , Q , RFP , RYL , SBH , SC , SCG , SFY , SHOO , SNAK , SNMX , STC , STRA , STRZA , SUP , SWC , TE , TEVA , TKR , TRP , TWC , UAN , UPL , USAK , VG , VICL , VNTV , VRX , WLT , WWE , XEL , XOM , XRAY Post your comment!